Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT03278782 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03278782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03278782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 14, 2017
Completion date
July 31, 2027
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent anaplastic large cell lymphoma, recurrent angioimmunoblastic t-cell lymphoma, recurrent mature t- and nk-cell non-hodgkin lymphoma, recurrent mycosis fungoides, recurrent primary cutaneous t-cell non-hodgkin lymphoma, refractory anaplastic large cell lymphoma, refractory angioimmunoblastic t-cell lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma, refractory mycosis fungoides, refractory peripheral t-cell lymphoma, not otherwise specified, refractory primary cutaneous t-cell non-hodgkin lymphoma